These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
112 related articles for article (PubMed ID: 28159504)
41. "Like it was just everyday business": A qualitative study of pharmacy-based naloxone and syringe customer experience. Gray M; Shin SS; Silcox J; Flores D; Bolivar D; Irwin AN; Floyd AS; Bratberg J; Boggis JS; Hartung DM; Green TC J Am Pharm Assoc (2003); 2023; 63(3):838-846. PubMed ID: 36872182 [TBL] [Abstract][Full Text] [Related]
42. Student pharmacist perceptions of participation in hands-on naloxone counseling. Hines J; Deja E; Black EP Curr Pharm Teach Learn; 2018 Jun; 10(6):712-716. PubMed ID: 30025770 [TBL] [Abstract][Full Text] [Related]
43. A naloxone and harm reduction educational program across four years of a doctor of pharmacy program. Maguire MA; Pavlakos RN; Mehta BH; Schmuhl KK; Beatty SJ Curr Pharm Teach Learn; 2018; 10(1):72-77. PubMed ID: 29248078 [TBL] [Abstract][Full Text] [Related]
44. First Responder knowledge, perception and confidence in administering naloxone: Impact of a pharmacist-provided educational program in rural Mississippi. Crocker A; Bloodworth L; Ballou J; Liles AM; Fleming L J Am Pharm Assoc (2003); 2019; 59(4S):S117-S121.e2. PubMed ID: 31109810 [TBL] [Abstract][Full Text] [Related]
45. Naloxone Administration for Opioid Overdose Reversal in the Prehospital Setting: Implications for Pharmacists. Weaver L; Palombi L; Bastianelli KMS J Pharm Pract; 2018 Feb; 31(1):91-98. PubMed ID: 28399697 [TBL] [Abstract][Full Text] [Related]
46. In-flight opioid overdose and the availability of onboard naloxone: An international survey of commercial airlines. Wang JJ; Poirier V; Carvalho AM; Biary R; Su MK Travel Med Infect Dis; 2019; 30():123-124. PubMed ID: 31216490 [No Abstract] [Full Text] [Related]
47. Survey of Southern Wisconsin Needle Exchange Clients Regarding Opioid Overdose and Naloxone Use. Baltes A; Devo B; Kaiser M; Birstler J; Brown RT WMJ; 2019 Jul; 118(2):84-87. PubMed ID: 31532934 [TBL] [Abstract][Full Text] [Related]
56. Expanding access to naloxone in the United States. Doyon S; Aks SE; Schaeffer S; ; ; Clin Toxicol (Phila); 2014 Dec; 52(10):989-92. PubMed ID: 25283253 [No Abstract] [Full Text] [Related]
57. Pilot implementation of the PharmNet naloxone program in an independent pharmacy. Eldridge LA; Meyerson BE; Agley J J Am Pharm Assoc (2003); 2023; 63(1):374-382.e12. PubMed ID: 36209035 [TBL] [Abstract][Full Text] [Related]
58. Is subcutaneous or intramuscular naloxone as effective as intravenous naloxone in the treatment of life-threatening heroin overdose? Wasiak J; Clavisi O Med J Aust; 2002 May; 176(10):495. PubMed ID: 12065016 [No Abstract] [Full Text] [Related]